On this page
Coronary artery disease
Also known as Coronary heart disease · Heart attack risk · CAD
For most people, coronary artery disease is not caused by a single faulty gene. Instead, hundreds of common DNA variants, each with a tiny individual effect, add together to shape lifetime risk. A polygenic risk score sums these variants into one estimate, explaining why heart disease often clusters in families without a clear single-gene inheritance pattern, and why risk lies on a smooth continuum across the population.
Available at Jeen Health
Clinical tests that include this
Overview
Coronary artery disease (CAD), also called coronary heart disease, is the build-up of fatty plaques (atherosclerosis) in the arteries that supply the heart muscle with blood. Over time these plaques narrow the arteries or rupture, causing angina, heart attacks (myocardial infarction) and some forms of heart failure. It is one of the most common and serious conditions in the UK: around 1.9 million people in England are living with coronary heart disease, and cardiovascular disease as a whole is among the leading causes of death, contributing to roughly one in four deaths nationally. Risk rises with age and is higher in men at younger ages, in people with diabetes, high blood pressure, raised cholesterol, obesity and in those who smoke. Deprivation and South Asian ancestry are also linked to higher rates. Both inherited and lifestyle factors contribute, which is why CAD is described as a complex, multifactorial condition.
Symptoms & clinical features
Coronary artery disease often develops silently over decades before any symptoms appear. The classic presentation is angina: chest tightness, pressure or pain, sometimes spreading to the arm, neck or jaw, typically brought on by exertion or stress and eased by rest. Breathlessness, fatigue and reduced exercise tolerance are common. The first sign can be a heart attack, with sustained central chest pain, sweating, nausea and breathlessness, which is a medical emergency requiring 999. Some people, particularly those with diabetes, women and older adults, have atypical or minimal symptoms. Importantly, having a high polygenic risk score does not change how coronary artery disease looks or feels: it influences the likelihood of developing disease, not the symptoms once it occurs. Anyone with suspected cardiac chest pain should seek urgent medical attention regardless of their genetic risk.
Video: Genetics 101
Affected organs
Coronary artery disease primarily affects the coronary arteries, the blood vessels supplying the heart muscle (myocardium). When these arteries narrow or block, the heart muscle itself is damaged, leading to angina, heart attack and heart failure. The underlying process, atherosclerosis, affects arteries throughout the body, so the same risk factors and genetics often also involve the arteries of the brain (stroke) and limbs (peripheral arterial disease), making it part of broader cardiovascular and circulatory system disease.
Risks & severity
A polygenic risk score is usually expressed as a percentile (for example, in the top 5% of the population) or as a relative risk compared with average. For coronary artery disease, individuals in the highest few percent of scores can carry roughly a threefold or greater increase in risk relative to those with average scores, which is why CAD is often cited as the condition where polygenic scoring shows most promise. However, a score describes probability across groups, not certainty for any one person: many high-score individuals never develop disease, and some low-score individuals do. Predictive performance also varies by ancestry. Many scores were derived largely from European-ancestry data and perform less well in other populations; the 9p21 signal, for instance, replicates poorly in people of African ancestry, reflecting ancestry-specific genetic structure at that locus.
Genetic causes
Coronary artery disease has a strongly polygenic architecture: large genome-wide association studies (GWAS) have now identified well over 200 common genetic loci linked to risk, most of them outside protein-coding regions and each contributing only a small effect. The best-known signal sits at the 9p21 locus (near the CDKN2A/CDKN2B genes and the CDKN2B-AS1/ANRIL non-coding RNA), one of the strongest and most replicated CAD associations worldwide. The LPA locus, which governs lipoprotein(a) levels, and SORT1 on chromosome 1p13, which influences LDL cholesterol, are other well-established contributors. Common variants in or near LDLR, the gene mutated in familial hypercholesterolaemia, also act as small-effect risk factors. A polygenic risk score aggregates the effects of these and many thousands of other variants. Together they capture inherited susceptibility that operates largely through lipids, blood pressure, inflammation and vascular biology rather than any single causal gene.
Inheritance pattern
Coronary artery disease does not follow simple (Mendelian) inheritance. Instead of one gene passed down with a clear dominant or recessive pattern, risk reflects the combined action of many common variants, each inherited independently from both parents. Because everyone carries a different mix of higher- and lower-risk variants, polygenic risk is spread across the population as a smooth, bell-shaped continuum rather than falling into distinct affected and unaffected groups. This is why CAD clusters in families without a predictable inheritance pattern: relatives share some, but not all, of these variants, alongside shared lifestyle and environment. Having a parent or sibling with early heart disease raises your own risk, partly through this shared polygenic background. A high score is not destiny: it shifts the odds, and much of that risk can be modified.
Diagnosis & testing
A polygenic risk score is not a diagnosis. It is a statistical estimate of inherited susceptibility, calculated by reading many common variants across your genome and weighting each by its known effect on coronary artery disease, then summing them into a single figure. It tells you where you sit on the population risk distribution, not whether you have disease now or definitely will. Diagnosing actual coronary artery disease is a separate clinical process, using symptoms, examination, blood tests (including cholesterol), an ECG, and imaging such as CT coronary angiography, stress testing or invasive angiography. A polygenic score is best understood as one additional input that can refine an overall risk picture, used alongside conventional risk factors, not as a replacement for clinical assessment or established cardiac investigations.
Management & lifestyle
For people identified as being at elevated polygenic risk, the emphasis is on earlier and more determined prevention rather than any disease-specific treatment. The key modifiable factors are well established: not smoking, maintaining a healthy weight, regular physical activity, a heart-healthy diet, limiting alcohol, and controlling blood pressure, blood glucose and cholesterol. A high score can prompt an earlier conversation with a GP about checking these factors and, where appropriate, starting cholesterol-lowering treatment such as statins. In the UK, adults aged 40 to 74 are offered the NHS Health Check, which estimates cardiovascular risk using tools like QRISK and guides decisions on lifestyle and medication. A polygenic score may help flag younger or borderline individuals for closer attention. Crucially, because so much CAD risk is modifiable, people at high genetic risk often gain the most from prevention; genetic risk raises the baseline but does not remove the benefit of these measures.
UK care pathway
The NHS does not routinely use polygenic risk scores for coronary artery disease. Cardiovascular risk in the UK is assessed mainly through the NHS Health Check, offered to adults aged 40 to 74 every five years, which combines blood pressure, cholesterol, age, ethnicity, smoking and other factors using the QRISK calculator to estimate 10-year risk. Based on that score, GPs discuss lifestyle changes and may offer statins. People with symptoms suggestive of angina are referred to rapid-access chest pain clinics or cardiology for investigation. A polygenic score sits outside, and alongside, this pathway.
Frequently asked questions
How is polygenic coronary artery disease risk different from a single-gene fault?
A single-gene fault, such as the LDLR mutations behind familial hypercholesterolaemia, is one rare, high-impact change that strongly raises risk on its own and follows a clear inheritance pattern. Polygenic risk is the opposite: hundreds of common variants, each with a tiny effect, add together. Most people's heart disease risk comes from this polygenic background rather than a single faulty gene, which is why risk is spread smoothly across the population instead of being all-or-nothing.
Is a polygenic risk score for heart disease available on the NHS?
Not routinely. The NHS currently assesses cardiovascular risk using the NHS Health Check (ages 40 to 74) and the QRISK calculator, not polygenic scores. Polygenic testing for coronary artery disease is presently available mainly through research studies and private providers. A score is best used to inform conversations with your GP about prevention, alongside, not instead of, standard NHS checks and any recommended treatment.
Does a high polygenic score mean I will definitely have a heart attack?
No. A polygenic risk score estimates probability, not certainty. Even people in the highest-risk group may never develop coronary artery disease, while some with low scores do. The score raises or lowers your baseline odds, but a large part of heart disease risk is modifiable through not smoking, diet, exercise, and controlling blood pressure and cholesterol, so people at high genetic risk often have the most to gain from prevention.
Does a polygenic risk score work equally well for everyone?
Not entirely. Predictive accuracy varies by condition and ancestry. Many coronary artery disease scores were developed mainly from European-ancestry data and tend to perform less well in people of other backgrounds; for example, the 9p21 signal replicates poorly in people of African ancestry. This is an active area of research, and scores should be interpreted with ancestry in mind and always alongside conventional risk factors.
References
- Balasubramanian S, Chowdhury YS. Isosorbide. 2026. PMID: 32491771
- Kopin L, Lowenstein C. Dyslipidemia. Annals of internal medicine. 2017. PMID: 29204622
- Akyuz A. Exercise and Coronary Heart Disease. Advances in experimental medicine and biology. 2020. PMID: 32342457
- Bugger H, Bode C. The vulnerable myocardium. Hamostaseologie. 2015. PMID: 29589349
- Katira A, Katira R. Colchicine in coronary artery disease. Postgraduate medical journal. 2022. PMID: 33782205
- January CT, Wann LS, Calkins H. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019. PMID: 30686041
- Dimitroglou Y, Sakalidis A, Mavroudis A. Lipoprotein-associated Phospholipase A2 in Coronary Artery Disease. Current topics in medicinal chemistry. 2022. PMID: 36305124
- January CT, Wann LS, Calkins H. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Journal of the American College of Cardiology. 2019. PMID: 30703431